A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Publication|Articles|September 29, 2026
Paganin October Cover Story References
Author(s)Walter Paganin, MD, PhD
Listen
0:00 / 0:00
Find the references for October cover story, "Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression," by Walter Paganin, MD, PhD, here.
Advertisement
1. Paganin W.
2. Fava GA, Rafanelli C.
3. McAllister-Williams RH, Arango C, Blier P, et al.
4. Rush AJ, Sackeim HA, Conway CR, et al.
5. Rush AJ, Aaronson ST, Demyttenaere K.
6. Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM.
7. McIntyre RS, Alsuwaidan M, Baune BT, et al.
8. Paganin W.
9. Raison CL, Rutherford RE, Woolwine BJ, et al.
10. McIntyre RS, Best MW, Bowie CR, et al.
Advertisement
Related to this article
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Advertisement
Advertisement